HRP20161317T1 - Terapijsko sredstvo za bolest koja se bazira na inhibitornom učinku čimbenika inhibitora migracije makrofaga - Google Patents

Terapijsko sredstvo za bolest koja se bazira na inhibitornom učinku čimbenika inhibitora migracije makrofaga Download PDF

Info

Publication number
HRP20161317T1
HRP20161317T1 HRP20161317TT HRP20161317T HRP20161317T1 HR P20161317 T1 HRP20161317 T1 HR P20161317T1 HR P20161317T T HRP20161317T T HR P20161317TT HR P20161317 T HRP20161317 T HR P20161317T HR P20161317 T1 HRP20161317 T1 HR P20161317T1
Authority
HR
Croatia
Prior art keywords
therapeutic agent
disease based
macrophage migration
inhibitory effect
inhibitory
Prior art date
Application number
HRP20161317TT
Other languages
English (en)
Croatian (hr)
Inventor
Keiichi Tanaka
Kimiko Morimoto
Original Assignee
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd. filed Critical Toyama Chemical Co., Ltd.
Publication of HRP20161317T1 publication Critical patent/HRP20161317T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
HRP20161317TT 2013-07-18 2014-07-17 Terapijsko sredstvo za bolest koja se bazira na inhibitornom učinku čimbenika inhibitora migracije makrofaga HRP20161317T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013149690 2013-07-18
PCT/JP2014/069026 WO2015008827A1 (ja) 2013-07-18 2014-07-17 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤
EP14826811.3A EP2929880B1 (en) 2013-07-18 2014-07-17 Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor

Publications (1)

Publication Number Publication Date
HRP20161317T1 true HRP20161317T1 (hr) 2016-12-16

Family

ID=52346269

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161317TT HRP20161317T1 (hr) 2013-07-18 2014-07-17 Terapijsko sredstvo za bolest koja se bazira na inhibitornom učinku čimbenika inhibitora migracije makrofaga
HRP20171497TT HRP20171497T1 (hr) 2013-07-18 2017-10-05 Terapeutsko sredstvo za bolesti uzrokovane inhibitornim učinkom faktora inhibicije migracije makrofaga

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20171497TT HRP20171497T1 (hr) 2013-07-18 2017-10-05 Terapeutsko sredstvo za bolesti uzrokovane inhibitornim učinkom faktora inhibicije migracije makrofaga

Country Status (22)

Country Link
US (3) US20150353519A1 (enExample)
EP (2) EP3078372B1 (enExample)
JP (2) JP5802868B2 (enExample)
CN (1) CN105407887B (enExample)
AU (1) AU2014291149B2 (enExample)
CA (1) CA2918325C (enExample)
CY (2) CY1118140T1 (enExample)
DK (2) DK3078372T3 (enExample)
ES (2) ES2642440T3 (enExample)
HR (2) HRP20161317T1 (enExample)
HU (2) HUE034661T2 (enExample)
IL (1) IL243550B (enExample)
LT (2) LT2929880T (enExample)
NO (1) NO3078372T3 (enExample)
PL (2) PL2929880T3 (enExample)
PT (2) PT2929880T (enExample)
RS (2) RS55394B1 (enExample)
RU (2) RU2750540C2 (enExample)
SI (2) SI2929880T1 (enExample)
SM (3) SMT201700080T1 (enExample)
TW (1) TWI603965B (enExample)
WO (1) WO2015008827A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137708A1 (zh) * 2017-01-26 2018-08-02 重庆莱美药业股份有限公司 一种纳米炭-铁复合体系及其组合物、制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5922755A (en) * 1993-04-09 1999-07-13 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
WO1997023714A1 (de) * 1995-12-21 1997-07-03 Siemens Aktiengesellschaft Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
BR112014002407A2 (pt) 2011-08-30 2017-02-21 Toyama Chemical Co Ltd método para melhorar a terapia contra doenças autoimunes tais como artrite reumatóide

Also Published As

Publication number Publication date
CA2918325C (en) 2018-06-26
RS55394B1 (sr) 2017-04-28
SMT201700080B (it) 2017-03-08
WO2015008827A1 (ja) 2015-01-22
SMT201700080T1 (it) 2017-03-08
EP3078372B1 (en) 2017-09-13
PL3078372T3 (pl) 2018-02-28
LT2929880T (lt) 2016-11-25
SI2929880T1 (sl) 2016-12-30
US9918963B2 (en) 2018-03-20
CY1118140T1 (el) 2017-06-28
AU2014291149A1 (en) 2016-02-11
EP2929880A1 (en) 2015-10-14
RU2750540C2 (ru) 2021-06-29
EP2929880A4 (en) 2015-10-14
US20160228404A1 (en) 2016-08-11
ES2642440T3 (es) 2017-11-16
AU2014291149B2 (en) 2017-05-04
DK3078372T3 (en) 2017-10-16
DK2929880T3 (da) 2017-01-02
HUE029800T2 (en) 2017-04-28
TW201536764A (zh) 2015-10-01
JP5802868B2 (ja) 2015-11-04
PT2929880T (pt) 2016-11-08
HUE034661T2 (en) 2018-02-28
EP2929880B1 (en) 2016-09-14
US20150353519A1 (en) 2015-12-10
EP3078372A1 (en) 2016-10-12
PT3078372T (pt) 2017-10-18
IL243550B (en) 2019-06-30
CN105407887A (zh) 2016-03-16
CA2918325A1 (en) 2015-01-22
HK1222556A1 (zh) 2017-07-07
JP6060231B2 (ja) 2017-01-11
CN105407887B (zh) 2018-09-04
SI3078372T1 (en) 2018-01-31
US20160228406A1 (en) 2016-08-11
ES2593527T3 (es) 2016-12-09
RU2641301C2 (ru) 2018-01-17
SMT201700606T1 (it) 2018-01-11
NO3078372T3 (enExample) 2018-02-10
RU2017131951A (ru) 2019-02-06
TWI603965B (zh) 2017-11-01
HRP20171497T1 (hr) 2017-11-17
IL243550A0 (en) 2016-02-29
LT3078372T (lt) 2017-11-27
RU2017131951A3 (enExample) 2020-12-18
RU2016105141A (ru) 2017-08-23
CY1119496T1 (el) 2018-03-07
JP2016034953A (ja) 2016-03-17
PL2929880T3 (pl) 2017-03-31
RS56489B1 (sr) 2018-01-31
JPWO2015008827A1 (ja) 2017-03-02

Similar Documents

Publication Publication Date Title
IL289975A (en) Use of cannabidiol in the treatment of dravet syndrome
DK3706796T3 (da) Eksosomerer som RNA terapeutikske midler
PT3506909T (pt) Análogos de 4¿-fosfato e oligonucleótidos compreendendo os mesmos
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
HUE071358T2 (hu) Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk
EP3373908A4 (en) SYSTEMS FOR RELEASING A PROBIOTIC
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
MA42458A (fr) Systèmes améliorés d'administration de nanoparticules
LT3592355T (lt) Kx2-391/kx-01, skirtas naudoti aktininės keratozės gydymui
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
BR112016024943A2 (pt) laquinimod para o tratamento de casos de esclerose múltipla remitente recorrente (emrr) com status de alta deficiência
LT3458045T (lt) Ebselenas, skirtas naudoti menjero ligos gydymui
EP3318265A4 (en) PEPTIDE WITH ANTIVIRAL EFFECT AND COMPOSITION THEREOF
LT3124048T (lt) Kompozicija skirta vartoti per burną gastroezofaginio refliukso ligos ar skausmo gydymui
PT4048229T (pt) Composição farmacêutica para utilização no tratamento de cistite de diversas etiologias
LT3621609T (lt) Sanfetrinemas arba jo druska arba esteris, skirtas naudoti mikobakterinės infekcijos gydyme
EA201692013A1 (ru) Новое применение n,n-бис-2-меркаптоэтил-изофталамида
HUE050606T2 (hu) Kv1.3 inhibitorok és gyógyászati alkalmazásuk
IT201700111990A1 (it) Scambiatore per uso medicale
DK2929880T3 (da) Terapeutisk middel til sygdom baseret på hæmmende effekt af makrofag-migrationshæmmende faktor
HRP20211309T1 (hr) N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti
IL271703B (en) Use of macroazapyridinophanes metal complexes in the treatment of diseases
RU2019113626A (ru) Средство, увеличивающее мозговой кровоток
CL2018001871A1 (es) Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario
TH77043B (th) การใช้โลหะเจืออะลูมินา-โครเมียมในการปรับสภาพด้วยความร้อน